Blackstone Inc’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
Other funds holding RETA
Blackstone Inc's RETA Position: Q3 2023 in Review
Blackstone Inc sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 340,793 shares — an estimated $34.7M sold.
Blackstone Inc first reported a position in RETA in Q2 2020 and held it in 13 quarters. The position peaked at $48.2M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Blackstone Inc reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Blackstone Inc sold 340,793 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $34.7M.
- Blackstone Inc first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 13 quarters.
- Blackstone Inc's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $48.2M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Blackstone Inc's 13F filing for Q3 2023, filed 14 Nov 2023.